<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877132</url>
  </required_header>
  <id_info>
    <org_study_id>RHASHC09706</org_study_id>
    <nct_id>NCT04877132</nct_id>
  </id_info>
  <brief_title>Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)</brief_title>
  <official_title>Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The objective of this program is to provide access to enzyme replacement therapy (ERT) with&#xD;
      olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could&#xD;
      not participate in the olipudase clinical trials. The program will provide access to&#xD;
      olipudase alfa prior to registration and the availability of commercial product (including&#xD;
      reimbursement where applicable) in the country of the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Sphingomyelin Lipidosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olipudase alfa (GZ402665)</intervention_name>
    <description>Patients will receive intravenous (IV) infusion of olipudase alfa</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients (adult and pediatric)&#xD;
&#xD;
          -  Unsolicited request for the patient from a site with at least 3 years of experience in&#xD;
             administration and safety management of ERT.&#xD;
&#xD;
          -  Written informed consent signed by the patient or the patient's parent(s)/guardian(s),&#xD;
             where applicable.&#xD;
&#xD;
          -  Documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes,&#xD;
             or cultured fibroblasts.&#xD;
&#xD;
        Adult patients&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Clinically documented advanced disease evidenced by defined thresholds for lung,&#xD;
             spleen, liver, and hematologic parameters.&#xD;
&#xD;
        Pediatric patients&#xD;
&#xD;
        - Age &gt;3 years and &lt;18 years or clinical diagnosis consistent with ASMD Type A/B or Type B.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All patients (adult and pediatric)&#xD;
&#xD;
          -  Active serious intercurrent illness which will preclude enrollment, significant liver&#xD;
             disease with etiology other than ASMD, Malignancy with poor prognosis, serious medical&#xD;
             or psychiatric condition that may preclude participation, or circumstances that may&#xD;
             interfere with compliance in this compassionate use program, requirement for recurrent&#xD;
             dose adjustment of anticoagulation treatment over the last 6 months.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  For female patients of childbearing potential, a positive serum pregnancy (β human&#xD;
             chorionic gonadotropin [HCG]) test result.&#xD;
&#xD;
          -  For female patients of childbearing potential and sexually active male patients,&#xD;
             unwillingness to abstain from heterosexual intercourse in accordance with their&#xD;
             preferred and usual lifestyle, or to use 2 acceptable, effective contraceptive&#xD;
             methods, while participating in this program and for 15 days after the last infusion&#xD;
             of olipudase alfa.&#xD;
&#xD;
          -  For pediatric patients, clinical diagnosis, or suspicion of infantile onset ASMD.&#xD;
             Genotype compatible with ASMD type A.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended: Contact-US@sanofi.com OR Toll free number for US &amp; Canada</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

